Search

Introduction: Chronic urticaria (CU) is frequently a debilitating skin condition characterized by recurrent and spontaneous wheal and flares with significant impact on quality of life. This systematic review examines the impact of CU on sexual health., Methods: A systematic review using PubMed, Embase, Web of Science, and Cochrane library databases was conducted for articles on sexual health in chronic urticaria., Results: The database search produced 741 articles, of which 14 articles met inclusion criteria. Study design, patient demographics, disease characteristics, measures used to assess sexuality or sexual function, and study results were independently extracted for each article by two researchers. Any discrepancies were resolved to consensus by a third reviewer. Sexual dysfunction was common in patients with CU and its severity is associated with increased disease activity and poor disease control., Conclusion: Sexual dysfunction is common in patients with CU, and it negatively affects their quality of life (QoL), body image, sleep quality, and mental health. Incorporating sexual health assessments into CU trials will allow for valuable insights into efficacy of study medications on this important QoL domain. Increased awareness of sexual impairment in CU is needed to provide comprehensive care., Competing Interests: Declarations. Conflict of Interest: Maria A. Aleshin has served as a consultant for AbbVie, Santa Ana Bio, and Mirador, as an advisory board member for Novartis, and has received research funding from UCB. Heather M. Holahan is a speaker for Novartis. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin and Skin Actives Scientific. Vivian Y. Shi is currently affiliated with the Department of Dermatology, University of Washington, Seattle, Washington, USA. Jennifer L. Hsiao is on the Board of Directors for the Hidradenitis Suppurativa Foundation, has served as a consultant for AbbVie, Aclaris, Boehringer Ingelheim, Incyte, Novartis, and UCB; as a speaker for AbbVie, Novartis, UCB; as an investigator for Amgen, Boehringer Ingelheim, and Incyte. Jennifer L. Hsiao is an editorial board member of Dermatology and Therapy. Jennifer L. Hsiao was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Sarah E. Park has nothing to disclose. Elaine Ma has nothing to disclose. Caitlyn Dagenet has nothing to disclose. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors., (© 2024. The Author(s).)

There is a paucity of bibliometric data on pediatric-focused hidradenitis suppurativa (HS) publications. To better characterize research trends in pediatric HS and gaps in literature, we systematically searched PubMed between 2012 and 2022 for publications on pediatric HS and collected data on study design, topic, country, and level of evidence. Of 109 articles that met inclusion criteria, less than half (44/109, 40.4%) were high level of evidence studies; the most common study types were case reports/series (41/109, 37.6%) and cross-sectional studies (25/109, 22.9%), and the most common study topics were HS treatments (44/109, 40.4%), comorbidities (20/109, 18.3%), and clinical presentation (14/109, 12.8%). Although there has been expansion of the pediatric HS literature in recent years, our study highlights the need for larger prospective studies and trials to improve our ability to optimally manage pediatric HS patients and identify predictors of disease progression and treatment response., (© 2024 Wiley Periodicals LLC.)